166 related articles for article (PubMed ID: 32483736)
21. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine.
Drugs R D; 2008; 9(2):131-5. PubMed ID: 18298131
[TBL] [Abstract][Full Text] [Related]
22. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide.
MacEwen EG; Kurzman ID; Rosenthal RC; Smith BW; Manley PA; Roush JK; Howard PE
J Natl Cancer Inst; 1989 Jun; 81(12):935-8. PubMed ID: 2733037
[TBL] [Abstract][Full Text] [Related]
23. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma.
Kleinerman ES; Snyder JS; Jaffe N
J Clin Oncol; 1991 Feb; 9(2):259-67. PubMed ID: 1988574
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
25. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.
Vail DM; MacEwen EG; Kurzman ID; Dubielzig RR; Helfand SC; Kisseberth WC; London CA; Obradovich JE; Madewell BR; Rodriguez CO
Clin Cancer Res; 1995 Oct; 1(10):1165-70. PubMed ID: 9815908
[TBL] [Abstract][Full Text] [Related]
26. Liposomal MTP-PE for the adjuvant therapy of osteosarcoma.
Kleinerman ES; Jaffe N
Prog Clin Biol Res; 1990; 343():263-79. PubMed ID: 2198583
[No Abstract] [Full Text] [Related]
27. Liposomal MTP-PE.
Gano JB; Kleinerman ES
J Pediatr Oncol Nurs; 1994 Oct; 11(4):161-3. PubMed ID: 7946146
[No Abstract] [Full Text] [Related]
28. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
[TBL] [Abstract][Full Text] [Related]
29. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
30. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
31. Liposomal muramyl tripeptide up-regulates interleukin-1 alpha, interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 gene expression in human monocytes.
Asano T; McWatters A; An T; Matsushima K; Kleinerman ES
J Pharmacol Exp Ther; 1994 Feb; 268(2):1032-9. PubMed ID: 8113959
[TBL] [Abstract][Full Text] [Related]
32. Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).
Barnes DJ; Dutton P; Bruland Ø; Gelderblom H; Faleti A; Bühnemann C; van Maldegem A; Johnson H; Poulton L; Love S; Tiemeier G; van Beelen E; Herbschleb K; Haddon C; Billingham L; Bradley K; Ferrari S; Palmerini E; Picci P; Dirksen U; Strauss SJ; Hogendoorn PCW; Buddingh E; Blay JY; Cleton-Jansen AM; Hassan AB
BMC Cancer; 2022 Jun; 22(1):629. PubMed ID: 35672690
[TBL] [Abstract][Full Text] [Related]
33. Liposomal MTP-PE: a promising new biologic response modifier.
Gano JB; Kleinerman ES
Oncol Nurs Forum; 1995 Jun; 22(5):809-16. PubMed ID: 7675688
[TBL] [Abstract][Full Text] [Related]
34. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity.
Kurzman ID; Cheng H; MacEwen EG
Cancer Biother; 1994; 9(2):113-21. PubMed ID: 7529085
[TBL] [Abstract][Full Text] [Related]
35. Distribution and fate of free and liposome-encapsulated [3H]nor-muramyl dipeptide and [3H]muramyl tripeptide phosphatidylethanolamine in mice.
Fogler WE; Wade R; Brundish DE; Fidler IJ
J Immunol; 1985 Aug; 135(2):1372-7. PubMed ID: 4008926
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patients.
Murray JL; Kleinerman ES; Cunningham JE; Tatom JR; Andrejcio K; Lepe-Zuniga J; Lamki LM; Rosenblum MG; Frost H; Gutterman JU
J Clin Oncol; 1989 Dec; 7(12):1915-25. PubMed ID: 2479721
[TBL] [Abstract][Full Text] [Related]
37. Comparative interaction of free and liposome-encapsulated nor-muramyl dipeptide or muramyl tripeptide phosphatidylethanolamine (3H-labelled) with human blood monocytes.
Fogler WE; Fidler IJ
Int J Immunopharmacol; 1987; 9(2):141-50. PubMed ID: 3583507
[TBL] [Abstract][Full Text] [Related]
38. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
Sone S; Utsugi T; Tandon P; Ogawara M
Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
[TBL] [Abstract][Full Text] [Related]
39. Mifamurtide in metastatic and recurrent osteosarcoma: a patient access study with pharmacokinetic, pharmacodynamic, and safety assessments.
Anderson PM; Meyers P; Kleinerman E; Venkatakrishnan K; Hughes DP; Herzog C; Huh W; Sutphin R; Vyas YM; Shen V; Warwick A; Yeager N; Oliva C; Wang B; Liu Y; Chou A
Pediatr Blood Cancer; 2014 Feb; 61(2):238-44. PubMed ID: 23997016
[TBL] [Abstract][Full Text] [Related]
40. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
Asano T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
